According to a recent LinkedIn post from Resolution Therapeutics, the company’s EMERALD clinical trial of its Regenerative Macrophage Therapy for advanced liver disease is underway at eight NHS hospitals in the U.K. and seven sites in Spain. The post highlights commentary from investigators at Royal Liverpool University Hospital, who discuss the burden of advanced liver disease, the need for new treatments, and their rationale for participating in these trials.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Resolution Therapeutics is progressing a multi-center, international clinical program in a high-need indication, which may support the therapeutic and commercial potential of its macrophage-based cell therapy platform if results are positive. For investors, the scale and academic-clinical engagement of EMERALD could indicate a strategy aimed at building robust clinical evidence and positioning the company competitively within the emerging cell therapy segment for liver disease.